DelveInsight launched a new report on Adrenoleukodystrophy Market Insights, Epidemiology and Market Forecast 2030.
DelveInsight’s ‘Adrenoleukodystrophy Market Report 2030’ delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Adrenoleukodystrophy is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. Currently, no drug is approved for the treatment of Adrenoleukodystrophy and the available treatment options include hormone replacement therapy, dietary therapy with Lorenzo’s oil and Hematopoietic stem cell transplantation, using either umbilical cord or bone marrow stem cells.
View our full report: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
Adrenoleukodystrophy Symptoms:
Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market
“Among the European five countries, Germany had the highest diagnosed prevalent population of ALD with 1,895 cases, followed by France and the United Kingdom. On the other hand, Italy had the lowest diagnosed prevalent population of 1,126 in 2017.”
Adrenoleukodystrophy Emerging Therapy Assessment:
1. Lenti D: Bluebird Bio
2. Leriglitazone: Minoryx Therapeutics, S.L.
The market size for ALD was USD 993 million in 2017 in the Seven Major Markets.
DelveInsight’s analysts estimate that the market is expected to experience a significant rise in the coming years.
Although, a noticeable growth can be seen in the upcoming year, owing to the launch of Lenti-D (Gene therapy; Bluebird Bio), and Leriglitazone (MIN-102) (Minoryx Therapeutics).
“The total market size of Adrenoleukodystrophy in Japan was USD 111.57 million in 2017.”
Table of contents
1 Key Insight2 Executive Summary of Adrenoleukodystrophy3 Adrenoleukodystrophy Market Overview at a Glance4 Disease Background and Overview: Adrenoleukodystrophy5 Case Reports6 Adrenoleukodystrophy Epidemiology and Patient Population7 United States Epidemiology8 EU5 Epidemiology9 Japan Epidemiology10 Current Adrenoleukodystrophy Treatment and Medical Practices11 Unmet needs12 Adrenoleukodystrophy Marketed Drugs13 Adrenoleukodystrophy Emerging Drugs14 Adrenoleukodystrophy 7MM Market Analysis15 United States16 EU-5 countries: Market Outlook17 Japan Market Outlook18 Adrenoleukodystrophy Market Drivers19 Adrenoleukodystrophy Market Barriers20 SWOT Analysis21 Reimbursement and market access22 Appendix23 DelveInsight Capabilities24 Disclaimer25 About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performanc
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/